These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The AXXESS™ self-expanding biolimus A9™ eluting stent system for coronary bifurcation lesions. Dubois CL; Wijns W EuroIntervention; 2010 Dec; 6 Suppl J():J130-4. PubMed ID: 21930477 [No Abstract] [Full Text] [Related]
25. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. Byrne RA; Iijima R; Mehilli J; Pinieck S; Bruskina O; Schömig A; Kastrati A JACC Cardiovasc Interv; 2009 Apr; 2(4):291-9. PubMed ID: 19463439 [TBL] [Abstract][Full Text] [Related]
26. Preliminary results of the hydroxyapatite nonpolymer-based sirolimus-eluting stent for the treatment of single de novo coronary lesions a first-in-human analysis of a third-generation drug-eluting stent system. Costa JR; Abizaid A; Costa R; Feres F; Tanajura LF; Abizaid A; Mattos LA; Staico R; Siqueira D; Sousa AG; Bonan R; Sousa JE JACC Cardiovasc Interv; 2008 Oct; 1(5):545-51. PubMed ID: 19463357 [TBL] [Abstract][Full Text] [Related]
30. A case of coronary rupture and pseudoaneurysm formation after fracture of implanted paclitaxel-eluting stents. Kawai Y; Kitayama M; Akao H; Motoyama A; Tsuchiya T; Kajinami K Cardiovasc Interv Ther; 2016 Jul; 31(3):231-7. PubMed ID: 25998891 [TBL] [Abstract][Full Text] [Related]
31. My stent is better than your stent...Or is it? Bates ER; Menees DS JACC Cardiovasc Interv; 2011 May; 4(5):551-3. PubMed ID: 21596328 [No Abstract] [Full Text] [Related]
32. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW; JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464 [TBL] [Abstract][Full Text] [Related]
33. Comparison of resolute zotarolimus-eluting stents and sirolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES IV trial. Ahn JM; Park DW; Kim YH; Song H; Cho YR; Kim WJ; Lee JY; Kang SJ; Lee SW; Lee CW; Park SW; Yun SC; Han S; Lee SY; Lee BK; Cho JH; Yang TH; Lee NH; Yang JY; Park JS; Shin WY; Kim MH; Bae JH; Kim MK; Yoon J; Park SJ Circ Cardiovasc Interv; 2012 Oct; 5(5):633-40. PubMed ID: 23048051 [TBL] [Abstract][Full Text] [Related]
34. First nine-month complete invasive assessment (angiography, IVUS, and OCT) of the novel NEVO sirolimus-eluting stent with biodegradable polymer. Abizaid A; Costa JR; Feres F Catheter Cardiovasc Interv; 2011 Jan; 77(1):49-51. PubMed ID: 20506126 [TBL] [Abstract][Full Text] [Related]
35. Symptomatic abnormal vessel wall reaction after implantation of the first generation sirolimus-eluting stent: a case series. Mostafa AE; Richardt G; Abdel-Wahab M Cardiovasc Revasc Med; 2012; 13(3):196-200. PubMed ID: 22652316 [TBL] [Abstract][Full Text] [Related]
36. Drug-eluting stent fracture: incidence, contributing factors, and clinical implications. Canan T; Lee MS Catheter Cardiovasc Interv; 2010 Feb; 75(2):237-45. PubMed ID: 20025045 [TBL] [Abstract][Full Text] [Related]
37. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions). Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA; JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545 [TBL] [Abstract][Full Text] [Related]
38. An everolimus-eluting stent versus a paclitaxel-eluting stent in small vessel coronary artery disease: a pooled analysis from the SPIRIT II and SPIRIT III trials. Bartorelli AL; Serruys PW; Miquel-Hébert K; Yu S; Pierson W; Stone GW; Catheter Cardiovasc Interv; 2010 Jul; 76(1):60-6. PubMed ID: 20578194 [TBL] [Abstract][Full Text] [Related]
39. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial. Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147 [TBL] [Abstract][Full Text] [Related]